# EDGAR Filing Document

**Accession Number:** 0001937964
**File Stem:** 0001420506-25-002661
**Filing Date:** 2025-8
**Character Count:** 21247
**Document Hash:** 1fde9d025181ea6ca7700e50a34eb695
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001420506-25-002661.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001420506-25-002661

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Artia Global Partners LP
- **CENTRAL INDEX KEY:** 0001937964

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-23071
- **FILM NUMBER:** 251280854

**BUSINESS ADDRESS:**
- **STREET 1:** 1395 BRICKELL AVENUE
- **STREET 2:** STE 800
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131
- **BUSINESS PHONE:** 3057101384

**MAIL ADDRESS:**
- **STREET 1:** 1395 BRICKELL AVENUE
- **STREET 2:** STE 800
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001937964

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Artia Global Partners LP

**Address:** 1395 BRICKELL AVENUE, MIAMI, FL 33131

**Telephone number:** 3057101384

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-23071

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                         | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                               | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| ALNYLAM PHARMACEUTICALS, INC.          | 02043Q107 | 05/08/2025     | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          17061 |                0 | FOR         |                                    17061 | FOR                         |  |
| AMGEN INC.                             | 031162100 | 05/23/2025     | Advisory vote to approve our executive compensation.                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |          10000 |                0 | FOR         |                                    10000 | FOR                         |  |
| ARCELLX, INC.                          | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                                           | SECTION 14A SAY-ON-PAY VOTES |         229085 |                0 | FOR         |                                   229085 | FOR                         |  |
| BIOGEN INC.                            | 09062X103 | 06/17/2025     | Say on Pay - To hold an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |          22800 |                0 | FOR         |                                    22800 | FOR                         |  |
| BOSTON SCIENTIFIC CORPORATION          | 101137107 | 05/01/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |         129700 |                0 | FOR         |                                   129700 | FOR                         |  |
| CHARLES RIVER LABORATORIES INTL., INC. | 159864107 | 05/20/2025     | Advisory Approval of 2024 Executive Officer Compensation                                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |           4430 |                0 | FOR         |                                     4430 | FOR                         |  |
| ELI LILLY AND COMPANY                  | 532457108 | 05/05/2025     | Approval, on an advisory basis, of the compensation paid to the company's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          11887 |                0 | FOR         |                                    11887 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC.         | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         306699 |                0 | FOR         |                                   306699 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC.         | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |         306699 |                0 | ONE YEAR    |                                   306699 | FOR                         |  |
| INSMED INCORPORATED                    | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         206192 |                0 | FOR         |                                   206192 | FOR                         |  |
| INTRA-CELLULAR THERAPIES, INC.         | 46116X101 | 03/27/2025     | To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to ITI's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement. | SECTION 14A SAY-ON-PAY VOTES |         219719 |                0 | FOR         |                                   219719 | FOR                         |  |
| INTUITIVE SURGICAL, INC.               | 46120E602 | 05/01/2025     | To approve, by advisory vote, the compensation of the Company's Named Executive Officers.                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |            551 |                0 | FOR         |                                      551 | FOR                         |  |
| JANUX THERAPEUTICS, INC.               | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |          38100 |                0 | FOR         |                                    38100 | FOR                         |  |
| JANUX THERAPEUTICS, INC.               | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |          38100 |                0 | ABSTAIN     |                                    38100 | AGAINST                     |  |
| MEREO BIOPHARMA GROUP PLC              | 589492107 | 05/13/2025     | That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (nonbinding) basis.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         421359 |                0 | THREE YEARS |                                   421359 | FOR                         |  |
| MEREO BIOPHARMA GROUP PLC              | 589492107 | 05/13/2025     | That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         421359 |                0 | FOR         |                                   421359 | FOR                         |  |
| MERUS N.V.                             | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         139100 |                0 | FOR         |                                   139100 | FOR                         |  |
| NEUROCRINE BIOSCIENCES, INC.           | 64125C109 | 05/21/2025     | Advisory vote on the compensation paid to the Company's named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |          14700 |                0 | FOR         |                                    14700 | FOR                         |  |
| NUVALENT, INC.                         | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |          45781 |                0 | FOR         |                                    45781 | FOR                         |  |
| ORUKA THERAPEUTICS, INC.               | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |           7333 |                0 | FOR         |                                     7333 | FOR                         |  |
| ORUKA THERAPEUTICS, INC.               | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |           7333 |                0 | ONE YEAR    |                                     7333 | FOR                         |  |
| PROTAGONIST THERAPEUTICS, INC.         | 74366E102 | 06/20/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |          22971 |                0 | FOR         |                                    22971 | FOR                         |  |
| QUEST DIAGNOSTICS INCORPORATED         | 74834L100 | 05/15/2025     | An advisory resolution to approve the executive officer compensation disclosed in the Company's 2025 proxy statement                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |          56717 |                0 | FOR         |                                    56717 | FOR                         |  |
| REGENERON PHARMACEUTICALS, INC.        | 75886F107 | 06/13/2025     | Proposal to approve, on an advisory basis, executive compensation.                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |          10000 |                0 | FOR         |                                    10000 | FOR                         |  |
| REVOLUTION MEDICINES, INC.             | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").           | SECTION 14A SAY-ON-PAY VOTES |          74260 |                0 | FOR         |                                    74260 | FOR                         |  |
| SCHOLAR ROCK HOLDING CORPORATION       | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         121206 |                0 | FOR         |                                   121206 | FOR                         |  |
| SPRINGWORKS THERAPEUTICS INC           | 85205L107 | 05/14/2025     | Non-binding advisory vote on executive compensation                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |           5951 |                0 | FOR         |                                     5951 | FOR                         |  |
| SPRINGWORKS THERAPEUTICS INC           | 85205L107 | 06/26/2025     | A proposal to approve, on a non-binding, advisory basis, certain compensation that may be paid or become payable to the Company's named executive officers in connection with the Merger.                                                                      | SECTION 14A SAY-ON-PAY VOTES |          63930 |                0 | FOR         |                                    63930 | FOR                         |  |
| TG THERAPEUTICS, INC.                  | 88322Q108 | 06/12/2025     | An advisory vote to approve the compensation of our named executive officers.                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |          34528 |                0 | ABSTAIN     |                                    34528 | AGAINST                     |  |
| TRAVERE THERAPEUTICS, INC.             | 89422G107 | 05/15/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |          30900 |                0 | FOR         |                                    30900 | FOR                         |  |
| UNITED THERAPEUTICS CORPORATION        | 91307C102 | 06/26/2025     | Advisory resolution to approve executive compensation.                                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |           5000 |                0 | FOR         |                                     5000 | FOR                         |  |
| VAXCYTE, INC.                          | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | ABSTAIN     |                                        1 | AGAINST                     |  |
| VERONA PHARMA PLC                      | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         476288 |                0 | FOR         |                                   476288 | FOR                         |  |
| VERTEX PHARMACEUTICALS INCORPORATED    | 92532F100 | 05/14/2025     | Advisory vote to approve named executive officer compensation.                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |             51 |                0 | FOR         |                                       51 | FOR                         |  |
| VIKING THERAPEUTICS INC                | 92686J106 | 05/20/2025     | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          90279 |                0 | FOR         |                                    90279 | FOR                         |  |
| VIRIDIAN THERAPEUTICS, INC.            | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |          19381 |                0 | FOR         |                                    19381 | FOR                         |  |
| XENON PHARMACEUTICALS INC              | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |          40000 |                0 | FOR         |                                    40000 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Artia Global Partners LP

**By (Signature):** William Verdi

**By (Printed Signature):** William Verdi

**By (Title):** Chief Financial Officer and Chief Compliance Officer

**Date:** 08/29/2025